Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Unilever N.V. ( UN - Analyst Report ) posted solid fourth quarter and full year 2012 results. The company recorded underlying (excluding the impact of currency, acquisitions and disposals) sales growth of 7.8% in the fourth quarter.
The increase was driven by volume and pricing gains of 4.8% and 2.9%, respectively. All the categories performed well in the quarter. Increased investment in innovation and brand building contributed to the growth.
This fast-moving consumer products giant also performed well in the emerging markets despite global macroeconomic headwinds and unfavorable foreign currency translations. Emerging markets underlying sales expanded 10.8% while developed markets grew 4% in the quarter.
Full Year 2012 Results
Unilever’s core earnings (excluding one-time items) increased 11% (in local currency) to Euro 1.57 per share ($2.02 per share*), driven by the improvement in operating profit, reduced financing costs, lower tax rates and currency.
Underlying sales grew 6.9% in the 2012, comprising volume growth of 3.4% and pricing gains of 3.3%. Emerging markets underlying sales expanded 11.4%, while developed markets grew 1.6% in the current reporting year.
Despite higher commodity costs, gross margin improved 10 basis points (bps) to 40.0% on a currency neutral basis. The improved results were driven by pricing gains, cost saving initiatives and improved mix. The company also invested in its brands and increased its advertising spending. Overhead costs declined 20 bps in the year owing to business restructuring initiatives, leading to 30 bps increase in core operating margin to 13.8%.
Segment Details
Personal Care: The segment delivered underlying sales growth of 11.5% in the fourth quarter, driven by volume gains of 7.2% and improved pricing of 4.0%. For full year, underlying sales increased 10.0%, with volume gains of 6.5% and pricing gains of 3.3%.
Home Care: The segment delivered underlying sales growth of 10.4% in the quarter, riding on volume growth of 7.0% and price increase of 3.1%. For full year, underlying sales increased 10.3%, with volume gains of 6.2% and pricing gains of 3.9%.
Foods: The segment’s underlying sales increased 1.3% in the quarter as a 1.4% positive impact from pricing, partially offset by a 0.1% decline in volumes. For full year, underlying sales increased 1.8%, driven by pricing gains of 2.7% and offset by volume declines of 0.9%.
Refreshments: The segment delivered underlying sales growth of 9.8% in the quarter, owing to volume growth of 6.7% and pricing increase of 2.9%. For full year, underlying sales increased 6.3%, with volume gains of 2.4% and pricing gains of 3.9%.
Overall, we are optimistic about Unilever’s wide portfolio of brands, which helps it to maintain a dominant share in the market. Unilever has been strengthening its portfolio by expanding through a number of acquisitions. Further, Unilever has been divesting its businesses to shed off its non-core operations, thereby optimizing resources and allocating them to more promising markets.
Unilever sold its North America frozen meals business (brands of Bertolli and P.F. Chang) to ConAgra Foods Inc. (CAG) in August 2012. More recently in early-January 2013, Unilever agreed to sell its Skippy peanut butter business to Minnesota-based meat producer Hormel Foods Corporation ( HRL - Analyst Report ) .
However, the company faces high commodity and raw material cost that is impacting its margins since last many quarters.
We expect an uncertain macro-economic environment, going forward. Though the company forecasts volume gains and strong free cash flow in the near-term, commodity cost inflation will continue to be a headwind.
Unilever holds a Zacks Rank #2 (Buy). Other stocks that are presently doing well and hold a favorable rank include B&G Foods, Inc ( BGS - Snapshot Report ) and Flower Foods, Inc ( FLO - Snapshot Report ) . Both the companies carry a Zacks Rank #1 (Strong Buy)
*Euro 1=$1.28608, i.e. average price for the year 2012.
Read the full reports :
Snapshot Report on BGS
Analyst Report on HRL
Analyst Report on UN
Snapshot Report on FLO